Evidence for a cyclic GMP-independent mechanism in the anti-platelet action of S-nitrosoglutathione - PubMed (original) (raw)
Evidence for a cyclic GMP-independent mechanism in the anti-platelet action of S-nitrosoglutathione
M P Gordge et al. Br J Pharmacol. 1998 May.
Abstract
1. We have measured the ability of a range of NO donor compounds to stimulate cyclic GMP accumulation and inhibit collagen-induced aggregation of human washed platelets. In addition, the rate of spontaneous release of NO from each donor has been measured spectrophotometrically by the oxidation of oxyhaemoglobin to methaemoglobin. The NO donors used were five s-nitrosothiol compounds: S-nitrosoglutathione (GSNO), S-nitrosocysteine (cysNO), S-nitroso-N-acetyl-DL-penicillamine (SNAP), S-nitroso-N-acetyl-cysteine (SNAC), S-nitrosohomocysteine (homocysNO), and two non-nitrosothiol compounds: diethylamine NONOate (DEANO) and sodium nitroprusside (SNP). 2. Using 10 microM of each donor compound, mean+/-s.e.mean rate of NO release ranged from 0.04+/-0.001 nmol min(-1) (for SNP) to 3.15+/-0.29 nmol min(-1) (for cysNO); cyclic GMP accumulation ranged from 0.43+/-0.05 pmol per 10(8) platelets (for SNP) to 2.67+/-0.31 pmol per 10(8) platelets (for cysNO), and inhibition of platelet aggregation ranged from 40+/-6.4% (for SNP) to 90+/-3.8% (for SNAC). 3. There was a significant positive correlation between the rate of NO release and the ability of the different NO donors to stimulate intra-platelet cyclic GMP accumulation (r = 0.83; P = 0.02). However, no significant correlation was observed between the rate of NO release and the inhibition of platelet aggregation by the different NO donors (r= -0.17), nor was there a significant correlation between cyclic GMP accumulation and inhibition of aggregation by the different NO donor compounds (r = 0.34). 4. Comparison of the dose-response curves obtained with GSNO, DEANO and 8-bromo cyclic GMP showed DEANO to be the most potent stimulator of intraplatelet cyclic GMP accumulation (P < 0.001 vs both GSNO and 8-bromo cyclic GMP), but GSNO to be the most potent inhibitor of platelet aggregation (P < 0.01 vs DEANO, and P < 0.001 vs 8-bromo cyclic GMP). 5. The rate of NO release from GSNO, and its ability both to stimulate intra-platelet cyclic GMP accumulation and to inhibit platelet aggregation, were all significantly diminished by the copper (I) (Cu+) chelating agent bathocuproine disulphonic acid (BCS). In contrast, BCS had no effect on either the rate of NO release, or the anti-platelet action of the non-nitrosothiol compound DEANO. 6. Cyclic GMP accumulation in response to GSNO (10(-9) 10(-5) M) was undetectable following treatment of platelets with ODQ (100 microM), a selective inhibitor of soluble guanylate cyclase. Despite this abolition of guanylate cyclase stimulation, GSNO retained some ability to inhibit aggregation, indicating the presence of a cyclic GMP-independent component in its anti-platelet action. However, this component was abolished following treatment of platelets with a combination of both ODQ and BCS, suggesting that Cu+ ions were required for the cyclic GMP-independent pathway to operate. 7. The cyclic GMP-independent action of GSNO, observed in ODQ-treated platelets, could not be explained by an increase in intra-platelet cyclic AMP. 8. The impermeable thiol modifying agent p-chloromercuriphenylsulphonic acid (CMPS) produced a concentration-dependent inhibition of aggregation of ODQ-treated platelets, accompanied by a progressive loss of detectable platelet surface thiol groups. Additional treatment with GSNO failed to increase the degree of aggregation inhibition, suggesting that a common pathway of thiol modification might be utilized by both GSNO and CMPS to elicit cyclic GMP-independent inhibition of platelet aggregation. 9. We conclude that NO donor compounds mediate inhibition of platelet aggregation by both cyclic GMP-dependent and -independent pathways. Cyclic GMP generation is related to the rate of spontaneous release of NO from the donor compound, but transfer of the NO signal to the cyclic GMP-independent pathway may depend upon a cellular system which involves both copper (I) (Cu+) ions and surface membrane thiol groups. The potent anti-platelet action of GSNO
Similar articles
- Copper chelation-induced reduction of the biological activity of S-nitrosothiols.
Gordge MP, Meyer DJ, Hothersall J, Neild GH, Payne NN, Noronha-Dutra A. Gordge MP, et al. Br J Pharmacol. 1995 Mar;114(5):1083-9. doi: 10.1111/j.1476-5381.1995.tb13317.x. Br J Pharmacol. 1995. PMID: 7780643 Free PMC article. - Inhibition of human platelet aggregation by nitric oxide donor drugs: relative contribution of cGMP-independent mechanisms.
Sogo N, Magid KS, Shaw CA, Webb DJ, Megson IL. Sogo N, et al. Biochem Biophys Res Commun. 2000 Dec 20;279(2):412-9. doi: 10.1006/bbrc.2000.3976. Biochem Biophys Res Commun. 2000. PMID: 11118301 - Role of a copper (I)-dependent enzyme in the anti-platelet action of S-nitrosoglutathione.
Gordge MP, Hothersall JS, Neild GH, Dutra AA. Gordge MP, et al. Br J Pharmacol. 1996 Oct;119(3):533-8. doi: 10.1111/j.1476-5381.1996.tb15704.x. Br J Pharmacol. 1996. PMID: 8894174 Free PMC article. - Cyclic nucleotides in platelet function.
Haslam RJ, Davidson MM, Fox JE, Lynham JA. Haslam RJ, et al. Thromb Haemost. 1978 Oct 31;40(2):232-40. Thromb Haemost. 1978. PMID: 216130 Review. - The redox pathway of S-nitrosoglutathione, glutathione and nitric oxide in cell to neuron communications.
Chiueh CC, Rauhala P. Chiueh CC, et al. Free Radic Res. 1999 Dec;31(6):641-50. doi: 10.1080/10715769900301211. Free Radic Res. 1999. PMID: 10630687 Review.
Cited by
- Inhibition of anti-IgE mediated human mast cell activation by NO donors is dependent on their NO release kinetics.
Yip KH, Leung FP, Huang Y, Lau HY. Yip KH, et al. Br J Pharmacol. 2009 Apr;156(8):1279-86. doi: 10.1111/j.1476-5381.2009.00120.x. Epub 2009 Mar 19. Br J Pharmacol. 2009. PMID: 19302592 Free PMC article. - Role of cyclic GMP on inhibition by nitric oxide donors of human eosinophil chemotaxis in vitro.
Thomazzi SM, Moreira J, Marcondes S, De Nucci G, Antunes E. Thomazzi SM, et al. Br J Pharmacol. 2004 Feb;141(4):653-60. doi: 10.1038/sj.bjp.0705661. Epub 2004 Jan 26. Br J Pharmacol. 2004. PMID: 14744805 Free PMC article. - Inhibition of human platelet aggregation by a novel S-nitrosothiol is abolished by haemoglobin and red blood cells in vitro: implications for anti-thrombotic therapy.
Megson IL, Sogo N, Mazzei FA, Butler AR, Walton JC, Webb DJ. Megson IL, et al. Br J Pharmacol. 2000 Dec;131(7):1391-8. doi: 10.1038/sj.bjp.0703731. Br J Pharmacol. 2000. PMID: 11090112 Free PMC article. - S-Nitrosoglutathione improves haemodynamics in early-onset pre-eclampsia.
Everett TR, Wilkinson IB, Mahendru AA, McEniery CM, Garner SF, Goodall AH, Lees CC. Everett TR, et al. Br J Clin Pharmacol. 2014 Sep;78(3):660-9. doi: 10.1111/bcp.12379. Br J Clin Pharmacol. 2014. PMID: 24627995 Free PMC article. Clinical Trial. - Platelet aggregation is affected by nitrosothiols in patients with chronic hepatitis: in vivo and in vitro studies.
Federico A, Filippelli A, Falciani M, Tuccillo C, Tiso A, Floreani A, Naccarato R, Rossi F, Del Vecchio Blanco C, Loguercio C. Federico A, et al. World J Gastroenterol. 2007 Jul 21;13(27):3677-83. doi: 10.3748/wjg.v13.i27.3677. World J Gastroenterol. 2007. PMID: 17659726 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous